Global Brain Tumor Drugs Market Insights Forecasts to 2033

• The Global Brain Tumor Drugs Market Size Was Estimated at USD 1.77 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 10.14% from 2023 to 2033
• The Worldwide Brain Tumor Drugs Market Size is Expected to Reach USD 4.65 Billion by 2033
• Asia Pacific is predicted to grow at the fastest CAGR throughout the projection period

The Global Brain Tumor Drugs Market Size is Anticipated to Exceed USD 4.65 Billion by 2033, Growing at a CAGR of 10.14% from 2023 to 2033. The market growth is attributed to rising neurological condition prevalence, rising healthcare costs, a hike in oncology drug approvals, rising pharmaceutical research and development expenditures, and advancements in cancer drug discovery.

Market Overview

The market for brain tumor drugs focuses on the discovery, manufacturing, and distribution of drugs, such as carmustine, cisplatin, methotrexate, and temozolomide, for treating brain tumors. An abnormal cell growth or mass in or around the central nervous system is referred to as a brain tumor, spinal tumor, or brain tumor. There are two types of brain tumors. Primary brain tumors originate in brain tissue, while secondary brain tumors, such as metastases, originate elsewhere in the body and spread to the brain. Occasionally beginning in nerve cell support cells, brain tumors one in every 100 US cancers spread from other body areas to the skull, resulting in tissue damage or other health issues.

Various government initiatives driving the demand for brain tumor drugs. For instance, the finance minister announced key healthcare initiatives in the Union Budget 2025-2026, including improved cancer treatment access, expanded medical education, and support for gig workers with a total allocation of Rs 98,311 crore.

The increasing number of FDA approvals of drugs used for brain tumors is driving the demand for drugs used for brain tumors. For example, The U.S. FDA approved a new drug for treating IDH-mutant low-grade glioma, a type of brain cancer. Vorasidenib is an anti-cancerous that targets a mutated gene called IDH, inhibiting its activity and reducing cancer growth.

The increasing number of neurological disorders in children and adults is driving the growth of the brain tumor drug market.

Report Coverage

This research report categorizes the market for the global brain tumor drugs market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global brain tumor drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global brain tumor drugs market.

Driving Factors

The brain tumor drugs market is growing owing to the rise in neurological disorders worldwide, with 182,520 US patients having primary brain tumors in 2021. This demand for treatment drugs is driven by longer life expectancy, increased infection exposure, and sedentary lifestyles. The brain tumor drugs market is expected to grow due to technological advancements, clinical trials, and regulatory support. Investment in research and development, personalized medicine, and emerging therapies like immunotherapy and targeted gene therapy are driving growth. Collaboration between healthcare institutions and pharmaceutical companies is fostering novel treatment approaches, while patient advocacy and support groups are raising awareness and funds.

Restraining Factors

Low diagnosis and treatment rates, high costs, side effects, and restricted reimbursement rules in developing nations are the primary challenges confronting the brain tumor drugs market.

Market Segmentation

The global brain tumor drugs market share is classified into drugs and end-user.

• The temozolomide segment accounted to grow at the fastest CAGR of 13.28% in 2023.

Based on the drugs, the global brain tumor drugs market is categorized into bevacizumab, temozolomide, and others. Among these, the temozolomide segment accounted to grow at the fastest CAGR of 13.28% in 2023. The segmental expansion is attributed to the enhancing the patient survival suffering from patient survival, highly stable at acidic pH, the first-line drug, greater bioavailability, permeability of the blood-brain barrier (BBB), potent radiosensitizer, showing greater therapeutic activity against malignant glioma of the brain. Temozolomide prevents the growth of the tumor by binding to the DNA and interfering with cell growth and division.

• The hospital pharmacy segment accounted for the largest share of 56.89% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the end-user, the global brain tumor drugs market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. Among these, the hospital pharmacy segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is attributed to the complex treatment of brain tumors, maintenance of dose regimen, frequent monitoring of patients, daily blood checkups, adequate diagnosis with proper prescription, and claim of health insurance provisions often require healthcare professionals or physicians that can easily accessible on hospital pharmacy.

Regional Segment Analysis of the Global Brain Tumor Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global brain tumor drugs market over the predicted timeframe.

North America is anticipated to hold the largest share of the global brain tumor drugs market over the forecast period. In North America, the brain tumor drugs market growth is owing to rising discoveries and innovations in new drugs, increasing awareness of cancer among society, highly advanced healthcare provision to patients in hospitals, government schemes, the presence of fitness clubs, and sophisticated diagnostic devices.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is owing to the Asia-Pacific area has a growing need for brain tumor treatment options and medicines due to the rising disease burden. Furthermore, the Indian market for brain tumor treatment grew at the highest rate in the Asia-Pacific area, while China's market share was the largest.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global brain tumor drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Emcure Pharmaceuticals Limited
• Novartis Oncology
• Astellas Pharma Inc.
• AstraZeneca plc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Teva Pharmaceuticals Industries Ltd.
• Novo Nordisk A/S
• Euro lab
• Aspen
• Neopharma
• Baxter International Inc.
• Bristol Myers Squib
• Celnova Pharma
• Sanofi
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2025, The Australian Government invested USD 20 million in research to support children, adolescents, and young adults with childhood brain cancers, including DIPG. Three universities applied for funding through the Medical Research Future Fund 2024 Paediatric Brain Cancer Research Grants.

• In June 2024, Scientists from Northwestern Medicine developed ultrasound technology for the treatment of glioblastoma. This novel technology penetrates the blood-brain barrier and provides a small dose of a chemotherapy drug cocktail. Scientists utilized doxorubicin in combination with immune checkpoint antibodies to enhance the immune system's recognition of malignant glioblastoma cells and reactivate lymphocytes for cancer cell attack.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global brain tumor drugs market based on the below-mentioned segments:

Global Brain Tumor Drugs Market, By Drugs

• Bevacizumab
• Temozolomide
• Others

Global Brain Tumor Drugs Market, By End-User

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Global Brain Tumor Drugs Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa